RxDoctor Payments Data

Constantine Peters, DO

Hospitalist · Naples, FLNPI 1114937562

Payments from drug & device makers

$895in general payments, 2019–2025

Across 80 payments — averaging $11.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$410
  • E.r. Squibb & Sons, L.L.C.$123
  • Merck$113
  • Amarin Pharma, Inc.$69
  • Novartis$54
  • Sanofi Pasteur Inc.$35
  • plus $89 from 4 others

What the payments were for

  • Food & beverage$895100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$895 in reported general payments places this provider in the 80th percentile of 1,570 hospitalist providers in Florida.

See all hospitalist providers in Florida

Medicare billing

Part B allowed, 2024
$143,407
Medicare patients
440
Services billed
1,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$7,925
JanuviaSitagliptin Phosphate26$7,444
EliquisApixaban12$6,192
Metformin Hcl42$398
Levetiracetam14$336
Pantoprazole Sodium13$329
Cefdinir16$300
Losartan Potassium22$290
Atorvastatin Calcium18$269
Venlafaxine Hcl12$269
Levothyroxine Sodium12$198
ClopidogrelClopidogrel Bisulfate20$162
Metoprolol Tartrate24$149
Potassium Chloride15$120
Furosemide19$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$113$7,44426 claims
PfizerEliquis$410$6,19212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,570 hospitalist providers in Florida.

Other hospitalist in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →